Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2025)

Crinetics Pharmaceuticals has reported Non-Current Deffered Revenue over the past 9 years, most recently at $3.8 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 19.01% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, down 19.01%, while the annual FY2025 figure was $3.8 million, 19.01% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $3.8 million at Crinetics Pharmaceuticals, down from $4.1 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $7.2 million in Q1 2022 and troughed at $2000.0 in Q4 2021.
  • A 5-year average of $4.1 million and a median of $4.7 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 91.3% in 2021 and later soared 304950.0% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $2000.0 in 2021, then soared by 304950.0% to $6.1 million in 2022, then decreased by 22.14% to $4.8 million in 2023, then dropped by 0.97% to $4.7 million in 2024, then decreased by 19.01% to $3.8 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for CRNX at $3.8 million in Q4 2025, $4.1 million in Q3 2025, and $4.0 million in Q2 2025.